Gynogen HP Dosage/Direction for Use

Assisted Reproductive Technologies: The recommended initial dose of Menotrophin (Gynogen HP) for patients who have received a GnRH agonist for pituitary suppression is 225 IU. Based on clinical monitoring (including serum estradiol levels and vaginal ultrasound results) subsequent dosing should be adjusted according to individual patient response. Adjustment in dose should not be made more frequently than once every two days and should not exceed 150 IU per adjustment. The maximum daily dose of Menotrophin (Gynogen HP) given should not exceed 450 IU and dosing beyond 20 days is not recommended.
Once adequate follicular development is evident, hCG (Pubergen) should be administered to induced final follicular maturation in preparation for oocyte retrieval. The administration of hCG must be withheld in cases where the ovaries are abnormally enlarged on the last day of therapy. This should reduce the chance of developing OHSS.
Administration: Dissolve the contents of the vial of Menotrophin (Gynogen HP) in one mL of sterile saline and administer either intramuscularly or subcutaneously immediately. Any unused reconstituted material should be discarded.